Company intelligence / Profile preview

Rumpus Therapeutics

Pennsylvania, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Rumpus Therapeutics advanced AR101 (enzastaurin), a small molecule PKCβ inhibitor, into pivotal study readiness for vascular Ehlers-Danlos syndrome (vEDS). The asset was acquired by Aytu BioPharma which has initiated pivotal development. There are currently no FDA-approved treatments for vEDS[3][2].

Therapeutic areas: Rare Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Denovo Biopharma

Beyond the preview

Go deeper on Rumpus Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rumpus Therapeutics.

Explore the full profile